Shangbay Capital

ShangBay Capital is a prominent venture capital firm established in 2015 and headquartered in Palo Alto, California. The firm specializes in early-stage investments within the medical device, biotechnology, and healthcare technology sectors. ShangBay Capital focuses on identifying and funding disruptive companies that address significant unmet clinical needs with novel ideas, aiming to generate favorable returns for its investors through venture equity participation.

The firm's investment philosophy emphasizes a collaborative approach, actively working with founders and entrepreneurs to build successful businesses. ShangBay Capital leverages its deep industry expertise and extensive network within the medical device and healthcare sectors to support product commercialization and startup growth. They have a strong track record of successful exits and have been recognized as a highly active investor in the healthcare device space.

ShangBay Capital's leadership team brings a combined experience of over 100 years, fostering deep ties to strategic partners and experienced innovators in disruptive technologies. This expertise allows the firm to understand global market opportunities, assess valuations for medical device companies, and build long-term relationships with founders. William Dai, the Founding Managing Partner, has been instrumental in leading the firm's investment initiatives and has been recognized among top healthcare investors.

The firm's portfolio includes a diverse range of companies such as Fluid Biomed, Venova Medical, Laplace Interventional, Luminopia, Solenic Medical, Noah Medical, Flare Therapeutics, Alleviant Medical, SetPoint Medical, and Contraline. ShangBay Capital typically invests in Pre-Seed, Seed, Series A, Series B, and Series C stages, demonstrating its commitment to nurturing companies from their earliest phases through significant growth.